Reply to Meijide et al

<span class="paragraphSection">T<span style="text-transform:lowercase;font-variant:small-caps;">o the</span> E<span style="text-transform:lowercase;font-variant:small-caps;">ditor</span>—We thank Meijide and colleagues [<a href="#CIT0001" class="reflinks">1</a>] for their interest in our article [<a href="#CIT0002" class="reflinks">2</a>]. They rightly point out that the short follow-up in the Strategic Timing of Antiretroviral Treatment (START) study [<a href="#CIT0003" class="reflinks">3</a>] and an inherent low cancer risk at study entry hampered our ability to identify factors independently associated with infection-unrelated malignancies. Efforts are under way to extend follow-up beyond 2017 among START participants. This will allow us to determine with more accuracy the predictors for infection-unrelated cancer and better understand the effects of immediate vs deferred combination antiretroviral therapy initiation on cancer risk. In the meantime, data from large prospective cohort studies with long follow-up remain an invaluable source to determine risk factors for cancer among Human Immunodeficiency Virus (HIV)-infected persons.</span>

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2j7bz6f
via IFTTT